Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis

Annals of Pharmacotherapy

Volumn 42, Issue 12, 2008, Pages 1859-1864

  Howard, Ashley ^a   Hoffman, Janet ^a   Sheth, Anjly ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Aspergillosis; Monitoring; Serum concentration; Voriconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; VORICONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS; BILIRUBIN BLOOD LEVEL; CANDIDEMIA; CANDIDIASIS; COLOR VISION DEFECT; CONFUSION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; EXTRAPYRAMIDAL SYMPTOM; FUSARIUM; GENETIC POLYMORPHISM; HALLUCINATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INDIVIDUALIZATION; LIVER TOXICITY; LOADING DRUG DOSE; MORTALITY; NEUROTOXICITY; PHOTOPHOBIA; PRIORITY JOURNAL; SCEDOSPORIUM APIOSPERMUM; SIDE EFFECT; VISUAL DISORDER;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; LIVER FUNCTION TESTS; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES; VISION DISORDERS;

EID: 57449117696     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L243     Document Type: Article

References (17)

1. Maschmeyer G, Haas A, Comely OA. Invasive aspergillosis: epidemiology, diagnosis, and management in immunocompromised patients. Drugs 2007;67:1567-601.
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
3. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disease Society of America. Clin Infect Dis 2008;46:327-60.
4. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008;61:17-25. Epub 12 Nov 2007. DOI 10.1093/jac/dkm389
5. Product information. VFend (voriconazole). New York: Pfizer, November 2006.
6. Scott LR, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infection. Drugs 2007;67:269-98.
7. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
8. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109:1532-5. DOI 10.1002/cncr.22568
9. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2. DOI 10.1128/AAC.50.4.1570-1572.2006
10. Lewis RE. What is the "therapeutic range" for voriconazole? Clin Infect Dis 2008;46:212-4. DOI 10.1086/524670
11. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Matchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. DOI 10.1086/524669
12. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35:1273-5.
13. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
14. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46:235-43. DOI 10.1177/0091270005283837
15. Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood N. Safety of voriconazole and dose individualization. Clin Infect Dis 2003;36:1087-8.
16. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006;44:819-26. DOI 10.1128/JCM.44.3.819-826.2006
17. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis 2004;39:1241-4.